Figure 3: HCF-based active immunotherapy improved the survival in tumor-bearing mice. After s.c. administration of CT26 colon cancer cells (day 0), 6-week-old BALB/c mice received a 300 μg dose of human HCF in alum on days 4, 7, and 11. Control animals received PBS in alum. Mice were monitored for survival as described in Figure 2(b). Mice survival was followed for 100 days after tumor challenge. Representative results of one of 2 independent experiments are shown.